Key Performance
More- Earnings Score: N/A
- Momentum Score: 75
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
The psychedelic medicine sector is advancing with regulatory momentum, as the first psilocybin compound achieved two positive Phase 3 results in treatment-resistant depression. The DEA increased its 2026 psilocybin production quota by 67%. Five companies—Helus Pharma, Compass Pathways, Relmada Therapeutics, Alto Neuroscience, and Axsome Therapeutics—are progressing clinical programs targeting depression, anxiety, cognitive impairment, bladder cancer, and Alzheimer's agitation.
02/26/2026, 12:07 PM • Benzinga
Law firm investigating potential claims against Alto Neuroscience after stock price dropped 69.99% following disappointing Phase 2b trial results for ALTO-100 depression treatment.
10/07/2025, 6:05 PM • GlobeNewswire
Levi & Korsinsky is notifying investors of a class action lawsuit against Alto Neuroscience regarding alleged securities fraud related to misleading statements about their product pipeline's effectiveness in treating major depressive disorder.
09/19/2025, 4:49 PM • GlobeNewswire
Rosen Law Firm alerts Alto Neuroscience investors about a securities class action lawsuit alleging false statements about the company's drug ALTO-100 and its effectiveness in treating major depressive disorder.
09/19/2025, 9:50 AM • GlobeNewswire
A class action lawsuit has been filed against Alto Neuroscience alleging misleading statements about their IPO and drug ALTO-100's effectiveness in treating major depressive disorder.
09/18/2025, 4:00 PM • GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
Faruqi & Faruqi is investigating potential securities claims against Alto Neuroscience after the company's stock dropped 69.99% following disappointing Phase 2b trial results for ALTO-100 in treating Major Depressive Disorder (MDD).
09/17/2025, 11:40 PM • GlobeNewswire
Rosen Law Firm alerts Alto Neuroscience investors about a securities class action lawsuit alleging false statements about the company's drug effectiveness and business prospects, with a September 19, 2025 lead plaintiff deadline.
09/15/2025, 8:58 PM • GlobeNewswire
Rosen Law Firm alerts Alto Neuroscience investors about a September 19, 2025 deadline for a securities class action lawsuit alleging false statements about the company's drug effectiveness and business prospects.
09/12/2025, 12:41 PM • GlobeNewswire
Faruqi & Faruqi is investigating potential claims against Alto Neuroscience after its stock price dropped 69.99% following disappointing Phase 2b trial results for ALTO-100 in treating Major Depressive Disorder (MDD).
09/11/2025, 7:18 PM • GlobeNewswire
Over 25 therapies from 20+ pharmaceutical companies are currently in various clinical trial stages for bipolar disorder treatment, with promising new drug candidates targeting different neurological mechanisms.
09/11/2025, 1:00 PM • GlobeNewswire
Pomerantz Law Firm filed a class action lawsuit against Alto Neuroscience for allegedly misleading investors about the effectiveness of its drug ALTO-100 in treating major depressive disorder, resulting in significant stock price decline.
09/10/2025, 10:00 AM • GlobeNewswire
Rosen Law Firm alerts Alto Neuroscience investors about a securities class action lawsuit alleging false statements about the company's drug ALTO-100's effectiveness in treating major depressive disorder, with a September 19, 2025 deadline for potential lead plaintiffs.
09/09/2025, 6:51 PM • GlobeNewswire
A class action lawsuit has been filed against Alto Neuroscience alleging misleading statements about their IPO and drug ALTO-100's effectiveness in treating major depressive disorder, with potential investor damages.
09/08/2025, 4:00 PM • GlobeNewswire
Rosen Law Firm alerts Alto Neuroscience investors about a potential securities class action lawsuit alleging false statements about the company's drug effectiveness and business prospects during its IPO and subsequent trading period.
09/05/2025, 12:30 PM • GlobeNewswire
PDE4B Inhibitor Market Poised for Strong Growth by 2034 | DelveInsight
The PDE4B inhibitors market is expected to surge significantly by 2034, with promising therapeutic potential across respiratory, dermatologic, and inflammatory diseases. Emerging therapies and clinical trials are driving market expansion, targeting conditions like COPD, asthma, and cognitive impairment associated with schizophrenia.
09/03/2025, 1:00 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.